-
Henlius Completes First Dosing in Head-to-Head Study of PD-1 Inhibitor HanSiZhuang
•
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in a head-to-head bridging study for its programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The study is evaluating serplulimab as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) against Roche’s PD-L1 inhibitor Tecentriq (atezolizumab), the…
-
JancsiTech Raises Tens of Millions in Angel Round Led by Yuanbio Venture Capital
•
JancsiTech, a precision nuclear medicine specialist based in Shenzhen, has reportedly raised “tens of millions” of renminbi in an angel financing round led by Yuanbio Venture Capital. Existing investor Sequoia Capital China also participated in the round. The proceeds will be directed towards research and development, innovation of intelligent medical…
-
FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment
•
US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA) for poziotinib, a treatment for previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations, received a complete response letter (CRL) from the US FDA. The CRL cited…
-
Sino Biological to Invest RMB 1 Billion in Beijing Bio-Pharmaceutical Park
•
Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140 million) to create a one-stop biological reagent and technology service platform. The initiative also includes the development of a comprehensive bio-pharmaceutical innovation service park in the Beijing Economic-Technological Development Area. As of the announcement date,…
-
Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment
•
China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine (LY03005) in China. The extended-release treatment for depression has received its first prescriptions and is being launched through a multi-channel strategy that includes hospitals, pharmacies, and online platforms. Drug Profile and MechanismToludesvenlafaxine is a new…
-
Hong Kong Researchers Identify New Target for Epilepsy Treatment
•
Researchers at the University of Hong Kong have published the results of a study that identifies a potential new therapeutic target for epilepsy treatment. The research builds on recent findings regarding the role of neuroinflammation caused by abnormal reactive glial cells, including astrocytes and microglia, in temporal lobe epilepsy (TLE).…
-
Hope Medicine Gains Global Approval for Phase II Trial of HMI-115
•
China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II clinical study for its monoclonal antibody (mAb) HMI-115, targeting the prolactin receptor (PRL R). The drug is being evaluated as a treatment for endometriosis, a condition that affects many women worldwide. This potential first-in-class (FIC)…
-
Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline
•
Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move is expected to significantly expand Full-Life’s pipeline, including two compounds nearing clinical trials, provide a second innovative peptide-focused discovery platform, and leverage its Radio Technology manufacturing and logistics platforms to advance compounds into clinical development.…
